FDA Approves Merck’s Capvaxive to Prevent Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 18 Years and Older

The approval of Capvaxive was based on results from three Phase III studies, which found that Capvaxive was beneficial in preventing invasive pneumococcal disease and pneumococcal pneumonia in both unvaccinated and vaccinated adults.